Clareon PanOptix Lenses for Cataracts
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the safety and performance of two special lenses, Clareon PanOptix Pro/Pro Toric IOL, for individuals needing cataract surgery in both eyes. These lenses improve vision for distant, intermediate, and near objects. The trial seeks participants with cataracts in both eyes who plan to undergo routine surgery. Participants must attend all study visits and sign a consent form. As an unphased trial, this study provides a unique opportunity to contribute to advancements in cataract treatment technology.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these intraocular lenses are safe for cataract surgery?
Research shows that the Clareon PanOptix Pro/Pro Toric lenses are generally safe and well-tolerated by patients. Their approval for use indicates a strong safety record. Studies have found that these lenses improve vision at various distances, such as far away, at arm's length, and up close. However, they should not be used if certain eye conditions exist, like a tear in the back part of the eye's lens capsule or damage to the fibers holding the lens in place. Overall, the safety data supports using these lenses in cataract surgery, but individual health conditions should be considered.12345
Why are researchers excited about this trial?
Researchers are excited about the Clareon PanOptix Pro/Pro Toric IOL lenses because they offer a trifocal solution designed to improve vision at multiple distances for cataract patients. Unlike traditional monofocal lenses that only enhance vision at one distance, these lenses aim to eliminate the need for glasses by providing clear vision close-up, at intermediate distances, and far away. Additionally, the PanOptix Pro Toric version addresses astigmatism, which is a common issue that affects vision clarity. This innovative approach could significantly enhance the quality of life for people with cataracts by reducing their dependence on corrective eyewear.
What evidence suggests that the Clareon PanOptix Lenses are effective for cataracts?
Research shows that the Clareon PanOptix Pro/Pro Toric lenses, studied in this trial, are designed to improve vision at various distances, including far away, at arm's length, and up close. These lenses aim to help individuals see clearly without glasses after cataract surgery. Although specific data on the Clareon version is limited, similar lenses have shown promising results. For instance, studies have found that many patients experience excellent vision quality, which makes everyday tasks easier. Overall, these lenses could potentially enhance vision for those undergoing cataract surgery.12456
Who Is on the Research Team?
Sr. Principal Clinical Trial Operations, Surgical
Principal Investigator
Alcon Research LLC
Are You a Good Fit for This Trial?
This trial is for individuals with cataracts in both eyes who need routine surgery and are willing to attend all study visits. They must understand and sign a consent form. People with certain eye conditions, previous eye surgeries, or those wanting monovision correction cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo cataract surgery in both eyes, with the second eye surgery occurring within 7 to 14 days of the first. The clouded lens will be removed by phacoemulsification, and the PanOptix Pro and/or PanOptix Pro Toric IOLs will be implanted.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with visual acuity assessments at Month 1 and Month 6 postoperative.
What Are the Treatments Tested in This Trial?
Interventions
- Clareon PanOptix Pro/Pro Toric IOL
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alcon Research
Lead Sponsor
Raquel C. Bono
Alcon Research
Chief Medical Officer since 2022
MD from Harvard Medical School
David Endicott
Alcon Research
Chief Executive Officer since 2018
MBA from University of Southern California